Deze vertaling wordt voorbereid. Voorlopig tonen we de oorspronkelijke Engelse versie.
Regelgeving en recht · 27-9-20211 min lezen
Prospective Grant of an Exclusive Patent License: Development of a Bispecific T Cell Engager for the Treatment and Cure of HIV-1
Lokale automatische vertaling · Oorspronkelijke brontaal
Samenvatting
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Gilead Sciences, Inc. ("Gilead") located in Foster City, CA.
Oorspronkelijke brontaal: Federal Register — All DocumentsOrigineel bericht openen →